This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.
Just look at any pharmaproduct website that is nothing but a sales brochure in a majority of cases. ROI drives pharma companies. In the past, pharmaproduct websites had a huge effect on whether a patient asks for an Rx. 5ive: It’s time to update clinical trial information. Want proof? 3d render ).
When online health seekers come to a pharmaproduct website they want to know “what’s in it for me?” ” and “how much the drug costs” Sure, they will go to the product safety information page but it’s too hard for them to comprehend. It’s a huge waste of space, money, and time.
In clinical trials, how many people experienced a listed side effect? Email is still a great digital marketing tool, and our audiences felt that if the email contained updated health information and tips for living with certain health problems, they would open and read it. First impressions are 94% design-related.
The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England Journal of Medicine. compared to standard therapy alone.
Compared with other emerging pharmaceutical markets (such as India and China, covered in previous Emerging Market Outsourcing Reports), Russian facilities lack many US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, meaning Russian manufacturing is more focused on the domestic market.
Don (PMN): Hi good morning everyone, welcome to the pharmamarketing podcast. My background for decades now is in the pharmamarketing and branding space, working with all sorts of pharmaproducts, devices, diagnostics. Do you connect patients with the clinical trial folks? Don (PMN): Wonderful.
The idea that the same consumer who was gleefully clicking a remote to escape from TV ads was going to click a mouse to interact with online ads joyfully will go down as one of the great marketing fantasies of all time. It’s estimated that DTC marketers spend at least 76% of their budgets on TV ads. This leads to a big problem.
Pharmaceutical companies need to be prepared to answer the call for increased demand and supply into new markets, ensuring the proper resources and logistics framework are in place. The following year, pharmaproduction at several US sites used by Pfizer, Merck, and Novartis in the south-east US stopped as Hurricane Florence approached.
In light of the Covid-19 pandemic, the war in Ukraine, and the Russian gas supply issue, several countries have called for onshoring, also referred to as reshoring; the bringing back of pharmaproduction to locations within national borders to mitigate costs, supply issues, and concerns regarding bilateral relations.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content